Chromatin immunoprecipitation (ChIP) data confirm that SETD6 impacts the binding of E2F1 and BRD4 at the same target loci, establishing a novel mechanism by which SETD6 methylation of E2F1 modulates gene regulation programs in prostate cancer cells. The gene discussed is BRD4; the disease is prostate cancer.